Rapid progression of prostate cancer in men with a BRCA2 mutation

S. A. Narod; S. Neuhausen; G. Vichodez; S. Armel; H. T. Lynch; P. Ghadirian; S. Cummings; O. Olopade; D. Stoppa-Lyonnet; F. Couch; T. Wagner; E. Warner; W. D. Foulkes; H. Saal; J. Weitzel; A. Tulman; A. Poll; R. Nam; P. Sun; Jessica Danquah; Susan Domchek; Nadine Tung; Peter Ainsworth; Douglas Horsman; Charmaine Kim-Sing; Christine Maugard; Andrea Eisen; Mary Daly; Wendy McKinnon; Marie Wood; Claudine Isaacs; Dawna Gilchrist; Beth Karlan; Raluca Nedelcu; Wendy Meschino; Judy Garber; Barbara Pasini; Siranoush Manoukian; Christina Bellati

doi:10.1038/sj.bjc.6604453

Rapid progression of prostate cancer in men with a BRCA2 mutation

S. A. Narod, S. Neuhausen, G. Vichodez, S. Armel, H. T. Lynch, P. Ghadirian, S. Cummings, O. Olopade, D. Stoppa-Lyonnet, F. Couch, T. Wagner, E. Warner, W. D. Foulkes, H. Saal, J. Weitzel, A. Tulman, A. Poll, R. Nam, P. Sun, Jessica DanquahSusan Domchek, Nadine Tung, Peter Ainsworth, Douglas Horsman, Charmaine Kim-Sing, Christine Maugard, Andrea Eisen, Mary Daly, Wendy McKinnon, Marie Wood, Claudine Isaacs, Dawna Gilchrist, Beth Karlan, Raluca Nedelcu, Wendy Meschino, Judy Garber, Barbara Pasini, Siranoush Manoukian, Christina Bellati

Research output: Contribution to journal › Article

106 Scopus citations

Abstract

Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.

Original language	English (US)
Pages (from-to)	371-374
Number of pages	4
Journal	British journal of cancer
Volume	99
Issue number	2
DOIs	https://doi.org/10.1038/sj.bjc.6604453
State	Published - Jul 22 2008

Keywords

BRCA1
BRCA2
Prostate cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/sj.bjc.6604453

Fingerprint Dive into the research topics of 'Rapid progression of prostate cancer in men with a BRCA2 mutation'. Together they form a unique fingerprint.

Cite this

Narod, S. A., Neuhausen, S., Vichodez, G., Armel, S., Lynch, H. T., Ghadirian, P., Cummings, S., Olopade, O., Stoppa-Lyonnet, D., Couch, F., Wagner, T., Warner, E., Foulkes, W. D., Saal, H., Weitzel, J., Tulman, A., Poll, A., Nam, R., Sun, P., ... Bellati, C. (2008). Rapid progression of prostate cancer in men with a BRCA2 mutation. British journal of cancer, 99(2), 371-374. https://doi.org/10.1038/sj.bjc.6604453

Rapid progression of prostate cancer in men with a BRCA2 mutation. / Narod, S. A.; Neuhausen, S.; Vichodez, G.; Armel, S.; Lynch, H. T.; Ghadirian, P.; Cummings, S.; Olopade, O.; Stoppa-Lyonnet, D.; Couch, F.; Wagner, T.; Warner, E.; Foulkes, W. D.; Saal, H.; Weitzel, J.; Tulman, A.; Poll, A.; Nam, R.; Sun, P.; Danquah, Jessica; Domchek, Susan; Tung, Nadine; Ainsworth, Peter; Horsman, Douglas; Kim-Sing, Charmaine; Maugard, Christine; Eisen, Andrea; Daly, Mary; McKinnon, Wendy; Wood, Marie; Isaacs, Claudine; Gilchrist, Dawna; Karlan, Beth; Nedelcu, Raluca; Meschino, Wendy; Garber, Judy; Pasini, Barbara; Manoukian, Siranoush; Bellati, Christina.

In: British journal of cancer, Vol. 99, No. 2, 22.07.2008, p. 371-374.

Research output: Contribution to journal › Article

Narod, SA, Neuhausen, S, Vichodez, G, Armel, S, Lynch, HT, Ghadirian, P, Cummings, S, Olopade, O, Stoppa-Lyonnet, D, Couch, F, Wagner, T, Warner, E, Foulkes, WD, Saal, H, Weitzel, J, Tulman, A, Poll, A, Nam, R, Sun, P, Danquah, J, Domchek, S, Tung, N, Ainsworth, P, Horsman, D, Kim-Sing, C, Maugard, C, Eisen, A, Daly, M, McKinnon, W, Wood, M, Isaacs, C, Gilchrist, D, Karlan, B, Nedelcu, R, Meschino, W, Garber, J, Pasini, B, Manoukian, S & Bellati, C 2008, 'Rapid progression of prostate cancer in men with a BRCA2 mutation', British journal of cancer, vol. 99, no. 2, pp. 371-374. https://doi.org/10.1038/sj.bjc.6604453

Narod, S. A. ; Neuhausen, S. ; Vichodez, G. ; Armel, S. ; Lynch, H. T. ; Ghadirian, P. ; Cummings, S. ; Olopade, O. ; Stoppa-Lyonnet, D. ; Couch, F. ; Wagner, T. ; Warner, E. ; Foulkes, W. D. ; Saal, H. ; Weitzel, J. ; Tulman, A. ; Poll, A. ; Nam, R. ; Sun, P. ; Danquah, Jessica ; Domchek, Susan ; Tung, Nadine ; Ainsworth, Peter ; Horsman, Douglas ; Kim-Sing, Charmaine ; Maugard, Christine ; Eisen, Andrea ; Daly, Mary ; McKinnon, Wendy ; Wood, Marie ; Isaacs, Claudine ; Gilchrist, Dawna ; Karlan, Beth ; Nedelcu, Raluca ; Meschino, Wendy ; Garber, Judy ; Pasini, Barbara ; Manoukian, Siranoush ; Bellati, Christina. / Rapid progression of prostate cancer in men with a BRCA2 mutation. In: British journal of cancer. 2008 ; Vol. 99, No. 2. pp. 371-374.

@article{d16b96cdfd32447cabc3f393d56dac94,

title = "Rapid progression of prostate cancer in men with a BRCA2 mutation",

abstract = "Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.",

keywords = "BRCA1, BRCA2, Prostate cancer",

author = "Narod, {S. A.} and S. Neuhausen and G. Vichodez and S. Armel and Lynch, {H. T.} and P. Ghadirian and S. Cummings and O. Olopade and D. Stoppa-Lyonnet and F. Couch and T. Wagner and E. Warner and Foulkes, {W. D.} and H. Saal and J. Weitzel and A. Tulman and A. Poll and R. Nam and P. Sun and Jessica Danquah and Susan Domchek and Nadine Tung and Peter Ainsworth and Douglas Horsman and Charmaine Kim-Sing and Christine Maugard and Andrea Eisen and Mary Daly and Wendy McKinnon and Marie Wood and Claudine Isaacs and Dawna Gilchrist and Beth Karlan and Raluca Nedelcu and Wendy Meschino and Judy Garber and Barbara Pasini and Siranoush Manoukian and Christina Bellati",

year = "2008",

month = jul,

day = "22",

doi = "10.1038/sj.bjc.6604453",

language = "English (US)",

volume = "99",

pages = "371--374",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Rapid progression of prostate cancer in men with a BRCA2 mutation

AU - Narod, S. A.

AU - Neuhausen, S.

AU - Vichodez, G.

AU - Armel, S.

AU - Lynch, H. T.

AU - Ghadirian, P.

AU - Cummings, S.

AU - Olopade, O.

AU - Stoppa-Lyonnet, D.

AU - Couch, F.

AU - Wagner, T.

AU - Warner, E.

AU - Foulkes, W. D.

AU - Saal, H.

AU - Weitzel, J.

AU - Tulman, A.

AU - Poll, A.

AU - Nam, R.

AU - Sun, P.

AU - Danquah, Jessica

AU - Domchek, Susan

AU - Tung, Nadine

AU - Ainsworth, Peter

AU - Horsman, Douglas

AU - Kim-Sing, Charmaine

AU - Maugard, Christine

AU - Eisen, Andrea

AU - Daly, Mary

AU - McKinnon, Wendy

AU - Wood, Marie

AU - Isaacs, Claudine

AU - Gilchrist, Dawna

AU - Karlan, Beth

AU - Nedelcu, Raluca

AU - Meschino, Wendy

AU - Garber, Judy

AU - Pasini, Barbara

AU - Manoukian, Siranoush

AU - Bellati, Christina

PY - 2008/7/22

Y1 - 2008/7/22

N2 - Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.

AB - Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.

KW - BRCA1

KW - BRCA2

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=48249136563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249136563&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604453

DO - 10.1038/sj.bjc.6604453

M3 - Article

C2 - 18577985

AN - SCOPUS:48249136563

VL - 99

SP - 371

EP - 374

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -